Adbiotech애드바이오텍

Adbiotech is growing revenue but still deeply loss-making, with heavy debt and a share price that has fallen sharply over the past year.

Adbiotech, a Korean biotech firm making antibody-based alternatives to vaccines and antibiotics for livestock, aquaculture and humans, reported trailing twelve-month revenue of about ₩12.6B through H1 2026 but an operating loss of about ₩4.4B. Its market value is about ₩61.7B at ₩1,983 per share, and the stock is down 41% over one year while up 13.1% over one month. The balance sheet carries about ₩14.5B of borrowings against ₩12.1B of cash, and the company paid no dividend.

What stands out

• Revenue rose 15.8% in 2025 to about ₩12.9B, but the company has still posted operating losses every year since 2021.
• Trailing operating margin is -35.1% and net margin is -28.1%, with free cash flow around -₩1.2B over the same period.
• Liabilities are 103.8% of equity, and borrowings of about ₩14.5B exceed cash of about ₩12.1B.
• Recent filings are dominated by convertible bond matters, including conversion-right exercises and amended bond decisions in September and October 2026.
• Recent news covers a partnership with a Kazakhstan K-beauty platform to target Central Asia, a commercial item rather than a financial result.
• Foreign ownership fell from 1.3% to 1.0% over the last 60 days, while 20-day retail investor flows were strongly positive.

What to watch

• Upcoming full-year results and whether losses narrow from the trailing figures.
• Further filings on convertible bond conversions and any new share issuance, which could dilute existing holders.
• Progress on the Central Asia distribution deal and whether it adds meaningful revenue; the data does not give its size.